Get started
CRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AG

CRISPR THERAPEUTICS AG

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

CRSP/N trade ideas

CRSP - Market Overreaction, looking for long entryCRSPR is possibly one of the most important medical discoveries of this century. Media reports of that it "might" cause cancer are clearly overblown as any scientist in the industry will tell you. Do your own due diligence there, this is clearly an overreaction. Fried foods might cause cancer too, doesnt seem to hurt YUM that much Will be looking for entry around the 200SMA in this and in NTLA and SGMO, two other companies doing CRSPR R&D.
NASDAQ:CRSPLong
by choilive
3
CRSP Bullish Pennet BREAK OUTLadies and gents. Overview this chart and everything I post. I have been trading the markets for 4 years straight with out missing more than 20 or 30 days in that whole time period. This chart shows a perfect example of how bullish patterns occurs and how they are bought. The most important lesson of this picture is to make sure you are a dip buyer and not the break out buyer. Beginner traders buy the break out, but pros buy the dips and sell the break out to the beginner traders!
NASDAQ:CRSPLong
by UnknownUnicorn2779697
2
Option Sale OpportunityCRSP is admittedly a VERY volatile name, but one with a big future and I believe a CL list stock at GS. On Friday, I was able to sell the May $45 puts for $1.90. If I am exercised, my cost basis will be $43.10, which puts it right in the support of the bottom of the last pullback. I would be OK getting exercised on that and I could exit for a small loss if it violated the low of that prior pullback. If I don't get exercised, I've earned roughly 4% of the strike price for 4 weeks exposure for a strike that is roughly 20% OTM. I can live with that, too, as one will come close to making my monthly car payment. Drawback: There is obviously an earnings report between now and expiration. Add your thoughts
NASDAQ:CRSPLong
by jhains2
1
Investing In Genomics Anyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment opportunities and ideas all over the world. Start with what you know and what you are involved in, in your day to day life’’. Following this advice, I will share what I think is a potentially fantastic opportunity for readers interested in investing in healthcare. This opportunity lies in CRISPR. Looking back in recent history, it took over 13 years and an immense amount of computing power to map out the human genome. The process started in 2001 and cost 2.7 billion USD, 12 years later in 2012 CRISPR based genome-editing was birthed. In 2013 the cost to sequence a human genome has dropped from 2.7billion USD to 1000 USD. This deflationary trend is projected to continue into the 2020s and 2030s thus implying human gene sequencing will get cheaper and more affordable over time. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome-editing platform that dares to address the most salient health issues. read more at www.patreon.com NASDAQ:CRSP Many Thanks. R.M.D
NASDAQ:CRSP
by couragepharm
Investing In GenomicsAnyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment opportunities and ideas all over the world. Start with what you know and what you are involved in, in your day to day life’’. Following this advice, I will share what I think is a potentially fantastic opportunity for readers interested in investing in healthcare. This opportunity lies in CRISPR. Looking back in recent history, it took over 13 years and an immense amount of computing power to map out the human genome. The process started in 2001 and cost 2.7 billion USD, 12 years later in 2012 CRISPR based genome-editing was birthed. In 2013 the cost to sequence a human genome has dropped from 2.7billion USD to 1000 USD. This deflationary trend is projected to continue into the 2020s and 2030s thus implying human gene sequencing will get cheaper and more affordable over time. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome-editing platform that dares to address the most salient health issues. read more at www.patreon.com NASDAQ:CRSP Many Thanks. R.M.D
NASDAQ:CRSP
by couragepharm